ZOLL Medical Corporation on Tuesday announced a definitive agreement to acquire Cardiac Science Corporation (CSC), a portfolio company of Aurora Resurgence, a Los Angeles-based private equity investment firm, for an undisclosed value.
With executive offices in Deerfield, Wisconsin, Cardiac Science Corporation (CSC) is leading provider of automated external defibrillators (AEDs), related services and accessories.
The company said sudden cardiac arrest (SCA), an abrupt disruption of the heart's function, which causes a lack of blood flow to vital organs, claims more than 350,000 lives each year in the US. If a victim does not receive CPR and early defibrillation from an AED, chances of survival decrease 10% with each passing minute.
ZOLL's lifesaving AED management programme technology reportedly enables dispatchers to communicate the locations of registered AEDs to callers reporting potential sudden cardiac arrest incidents.
Hence, Cardiac Science's addition to ZOLL's AED Link programme will allow more 9-1-1 agencies to help put AEDs in the hands of laypersons and first responders to support life-saving action.
ZOLL Medical develops and markets medical devices and software solutions to advance emergency care and save lives and part of Asahi Kasei Group company.
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures
Probi launches new human and pet biotics ranges
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions